Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma Authors: James William Smithy, Allison Betof, Sebastian Klobuch, Troels Holz Borch, Hannah L Kalvin, Nitzan Hasson, Shirly Grynberg, Rodabe Amaria, Juliane A Czapla, Megan D Schollenberger, Andrew J S Furness, Jessica C Hassel, Martin Wermke, Sidsel Pedersen, Inge Marie Svane, Antonio Ocejo, Elizabeth Buchbinder, Douglas B Johnson, Michael Postow, Cristy Los, Jose Lutzky, Evan J Lipson, Ryan J Sullivan, Harriet M Kluger, Katherine S Panageas, Marco Donia, John B A G Haanen, Alexander Noor Shoushtari Published: 2026 ABSTRACT AbstractPurposeTreatment strategies for patients with advanced melanoma resistant to adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) remain undefined. The efficacy of immune checkpoint inhibitors (ICIs) after TIL has not been previously described.Patients and methodsPatients with unresectable melanoma who received ICI therapy both before and after TIL treatment were retrospectively identified at 14 international centers. Safety was evaluated among all patients that received one dose of ICI therapy after TIL. Objective response rates (ORR) were determined based on investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 responses based on radiology reports. Kaplan-Meier methodology was used to estimate overall survival (OS) and melanoma-specific survival.ResultsAmong 133 patients assessed for response to ICI therapy after progression on TIL therapy, the ORR was 11% (n=14; 95% CI 5.9% to 17%), including 3 complete responses (2.3%) and 11 partial responses (8.3%). Among patients treated with a programmed death-1 inhibitor prior to TIL (n=121), the ORR was 8.3% (95% CI 4.0% to 15%). At a median follow-up among survivors of 21 months, median OS from post-TIL ICI was 8.8 months (95% CI 6.5 to 12 months). Among 14 patients with response to post-TIL ICI, 13 received an ICI they had not previously received. In the safety cohort (n=138), post-TIL ICI therapy-related toxicity occurred in 31 patients(22%), among which 7 patients (5.1%) experienced recurrence of an adverse event experienced with prior ICI treatment.ConclusionEfficacy with ICI after TIL was limited, with no evidence of synergistic toxicity. As TIL therapy becomes more widely available, these data highlight the need for novel therapies in this setting and support the inclusion of this population in future clinical trials.Keywords: Adoptive cell therapy - ACT, Immune Checkpoint Inhibitor, Skin Cancer Introduction Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) has emerged as a promising therapeutic modality in patients with anti-programmed death-1 (PD-1) refractory melanoma and has become a standard of care in the USA following the Food and Drug Administration approval of lifileucel.1 Similarly, longstanding international academic cellular therapy programs have established TIL therapy as a treatment option in the Netherlands, Denmark, and Israel.2,4 Lifileucel has been associated with objective response rates of 31% in patients with anti-PD-1 refractory unresectable melanoma,5 6 with a subset of patients experiencing ongoing responses at 5 years.7 In a randomized European trial, TIL therapy was associated with improved progression-free survival (PFS) compared with ipilimumab monotherapy.3 The optimal sequencing of TIL therapy relative to other approved regimens remains undefined, and resistance is common. As TIL therapy becomes more widely adopted, the number of patients with TIL-refractory melanoma will likely increase. There is limited evidence to guide therapy selection for patients with disease progression after TIL therapy. A key unanswered question is whether treatment with immune checkpoint inhibitors (ICIs) administered after TIL can elicit effective anti-melanoma immune responses by reinvigorating a repertoire of adoptively transferred, potentially exhausted TILs. Similarly, it is unknown whether ICI therapy increases the likelihood or severity of immune-related adverse events (irAEs) after adoptive TIL transfer due to potential synergistic immune activation. To address these questions, we retrospectively assessed safety and efficacy of subsequent ICI therapy in patients with ICI-refractory and TIL-refractory advanced melanoma across 14 international melanoma centers. Methods Data and patients After obtaining a waiver of consent from local institutional review boards, we identified patients with unresectable melanoma treated with ICI therapy both before and after TIL treatment between 2012 and 2023 at 14 international cancer centers. Targeted therapy with BRAF±MEK inhibitors was permitted as intervening therapy between pre-TIL ICI and TIL infusion; progressive disease after TIL therapy was required prior to subsequent ICI therapy. To ensure the broadest understanding of ICI efficacy after TIL, and reflect varied practice patterns worldwide during the time frame of study conduct, patients were not required to have PD-1 inhibition prior to TIL. Patients included in efficacy analyses had data available regarding response to post-TIL ICI therapy (Efficacy Cohort). Toxicity analyses included additional patients for whom response data were unavailable (Safety Cohort). Tumor responses were assessed using investigator determination of response by Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 criteria based on radiology reports and imaging. Objective response rate (ORR) was the proportion of patients experiencing a complete response (CR) or a partial response (PR) as their best post-TIL ICI outcome. Disease control rate (DCR) was the proportion of patients experiencing a CR, PR, or stable disease (SD) as their best post-TIL outcome. Statistics Categorical variables were summarized using descriptive measures, and continuous variables using medians and IQRs. ORR and DCR were summarized as proportions with exact 95% CIs. Follow-up time was measured from the start of post-TIL ICI therapy to the date of last follow-up for survivors. Kaplan-Meier methods were used to estimate time-to-event outcomes. Overall survival (OS) was defined as time from start of ICI rechallenge to death from any cause or last follow-up, and melanoma-specific survival (MSS) as time from start of ICI rechallenge to melanoma-related death or last follow-up. Patients alive at last follow-up were censored. All analyses were conducted using R V.4.4.0.8 Results Patients and treatments Across 14 academic centers, 133 patients with documented response assessments to ICI therapy after TIL were identified, along with 5 additional patients with toxicity data only. During the study period, 408 patients received TIL for melanoma at the participating centers. Characteristics of 133 patients in the Efficacy Cohort are detailed in table 1. Most had cutaneous melanoma (75%) and had received a median of two prior lines of therapy before TIL (IQR 1–3). Nearly all patients (n=121; 91.0%) had prior anti-PD-1-based treatment, and 53 (40%) received nivolumab+ipilimumab (nivo-ipi) prior to TIL administration. 59 patients (44.4%) received more than one ICI regimen prior to TIL. Table 1Baseline characteristicsCharacteristicN=133*Sex Female64 (48) Male69 (52)Age at TIL infusion55 (46–61)Region USA55 (41) Europe67 (50) Israel11 (8.3)BRAF V600E/K mutated No80 (60) Yes53 (40)Melanoma subtype Cutaneous100 (75) Mucosal13 (9.8) Unknown primary13 (9.8) Acral7 (5.3)ECOG status at post-TIL ICI 068 (53) 149 (38) 210 (7.8) 31 (0.8) Unknown5Best response to TIL therapy CR1 (0.8) PR45 (34) SD44 (33) PD43 (32)M stage at ICI rechallenge M1a8 (6.0) M1b8 (6.0) M1c79 (59) M1d37 (28) Stage III unresectable1 (0.8)LDH elevated at ICI rechallenge No70 (54) Yes60 (46) Unknown3Liver metastases at ICI rechallenge No80 (61) Yes52 (39) Unknown1 Pre-TIL therapies Number of lines of systemic therapy prior to TIL Median (IQR)2.00 (1.00–3.00) Range1.00–9.00PD-1 monotherapy No34 (26) Yes99 (74)BRAFi or BRAFi+MEKi No113 (85) Yes20 (15)Ipilimumab+nivolumab No79 (59) Yes54 (41)Ipilimumab monotherapy No101 (76) Yes32 (24)Nivolumab-relatlimab FDC No126 (95) Yes7 (5.3)*n (%); median (IQR).CR, complete response; ECOG, Eastern Cooperative Oncology Group; FDC, fixed dose combination; ICIs, immune checkpoint inhibitors; LDH, lactate dehydrogenase; PD-1, programmed death-1; PD, progressive disease; PR, partial response; SD, stable disease; TILs, tumor-infiltrating lymphocytes. Baseline characteristics n (%); median (IQR). CR, complete response; ECOG, Eastern Cooperative Oncology Group; FDC, fixed dose combination; ICIs, immune checkpoint inhibitors; LDH, lactate dehydrogenase; PD-1, programmed death-1; PD, progressive disease; PR, partial response; SD, stable disease; TILs, tumor-infiltrating lymphocytes. At the time of post-TIL ICI therapy, 87% of patients had M1c or M1d disease, and lactate dehydrogenase (LDH) was elevated in 47%. Post-TIL ICI regimens included nivo-ipi (n=50; 38%), anti-PD-1 monotherapy (n=37; 28%), ipilimumab monotherapy (n=22; 17%), nivolumab+relatlimab (nivo-rela; n=14; 11%), and investigational anti-PD-1-based combinations (n=8; 6%). The median duration of treatment was 9 weeks (IQR 4–17). Reasons for treatment discontinuation were known in 127 patients and included disease progression in 101 patients, death in 4 patients, toxicity in 15 patients, and elective cessation (not due to progressive disease or toxicity) in 7 patients. Efficacy Post-TIL ICI therapy was associated with an ORR of 11% (n=14; 95% CI 5.9% to 17%) among 133 patients in the Efficacy Cohort, with CRs observed in 3 patients (2.3%) and PRs observed in 11 patients (8.3%). The ORR was similar among patients with anti-PD-1 exposure prior to TIL (ORR: 8.3%; 95% CI 4.0% to 15%; n=121), as well as among patients that experienced a PR or CR to TIL therapy (ORR: 13%; 95% CI 4.9% to 26%; n=46). The best response was SD in 12 patients, leading to a DCR of 20% (95% CI 13% to 27%). Rates of LDH elevation, Eastern Cooperative Oncology Group (ECOG) status, prior treatment lines, and M stage were similar between patients with and without response (online supplemental table S1). The median time between TIL infusion and ICI therapy was 8 months (IQR 5–13 months) in responders and 5 months (IQR 3–10 months) in non-responders (p=0.2; online supplemental figure S1). Among the 37 patients with M1d melanoma at the time of first post-TIL ICI, 2 patients had a best response of PR and 4 patients had a best response of SD. The median follow-up among survivors was 21 months (IQR 9–33). Median OS from the start of post-TIL ICI therapy was 8.8 months (95% CI 6.5 to 12 months), with a 2-year OS of 19% (95% CI 13% to 28%; figure 1A). Median MSS was 9.9 months (95% CI 7.0 to 13 months) with a 2-year MSS of 21% (95% CI 14% to 30%); all but five deaths were attributed to melanoma. (A) Overall survival from time of ICI rechallenge in the Efficacy Cohort (N=133). (B) Event history plot for patients with complete or partial response to post-TIL ICI therapy (N=14), from time of ICI rechallenge. Each patient represented is represented as a row and the colored bar represents duration of their first post-TIL ICI treatment. Treatment information following initial ICI post-TIL was not collected and is marked by light gray lines. Response timing is captured for those that had dates available. Treatments received prior to TIL infusion are represented in colored squares and are not ordered sequentially. CR, complete response; ICI, immune checkpoint inhibitor; PD-1, programmed death-1; PR, partial response; TIL, tumor-infiltrating lymphocyte. Among 14 patients with CR or PR to post-TIL ICI, 13 received an ICI targeting a checkpoint after TIL that they had not previously received (figure 1B). Of the 45 patients that received an ICI treatment post TIL that they had also received prior to TIL (ie, did not have a new ICI exposure after TIL), 1 patient receiving nivo-ipi both before and after TIL experienced a PR (2.2%) and 6 patients (13%) had a best response of SD to post-TIL ICI (13%). Additional treatment details for these 7 patients are included in online supplemental table S2. In a subset analysis of patients treated with a therapy targeting a novel immune checkpoint not used before TIL (n=88), the ORR was 15% (95% CI 8.1% to 24%) including 3 CRs (3%) and 10 PRs (11%). Among the 30 patients who had received anti-PD-1 monotherapy before TIL and were later treated with nivo-ipi after TIL, the ORR was 13% (95% CI 3.8% to 31%). Of the 12 patients that received nivo-ipi prior to TIL and then received nivo-rela as the first ICI therapy after TIL, 1 patient had a best response of PR (8.3%), 3 (25%) had SD, and 8 (67%) had progressive disease. Among patients without prior exposure to a PD-1 targeting antibody prior to TIL (n=12), the ORR was 33% (95% CI 9.9% to 65%). Toxicity In the Safety Cohort (n=138), toxicity was observed in 31 patients (24%). Of these, 7 patients (5.1%) experienced recurrence of an adverse event previously observed with prior ICI therapy (figure 2). 14 grade 3+AEs were reported in 11 patients (8%), including four cases each of colitis and pneumonitis, and one case each of dermatomyositis, gastritis, immune-mediated cytopenias, hepatitis, myositis, and thyroiditis. Three of the grade 3+AEs occurred in patients with recurrent toxicity. No treatment-related deaths were attributed to ICI therapy after TIL. Proportion of patients experiencing toxicity to ICI rechallenge (N=138). ICI, immune checkpoint inhibitor; irAE, immune-related adverse event. Discussion As the population of patients with TIL-refractory melanoma grows, identifying effective post-TIL therapies is increasingly important. Finding options for patients with progression after TIL can be complicated by poor performance status, ongoing lymphopenia, and need for antimicrobial prophylaxis. Thus, standard of care ICI regimens are often considered. In this large, multicenter analysis, ICI therapy after TIL demonstrated limited clinical activity, with nearly all responses occurring after introduction of a new ICI regimen. These findings do not support the hypothesis that adoptive TIL transfer enhances response to subsequent ICI therapy. The single patient who responded to a previously administered regimen received nivo-ipi both before and after TIL infusion, and meaningful responses to nivo-ipi rechallenge have been reported without intervening adoptive TIL transfer.9 10 Interestingly, the response rate to nivo-ipi after TIL in the subgroup of patients previously exposed to anti-PD-1 monotherapy was only 13%, which appears lower than that observed in SWOG S1616.11 This observation raises the question of whether TIL therapy may compromise responsiveness to subsequent combination ICI therapy. As lymphodepleting chemotherapy for TIL can cause prolonged lymphopenia,12 there is a strong biologic rationale for this hypothesis. Alternatively, poorer outcomes in this cohort may reflect the severity of their disease, or that would-be responders to subsequent ICI were selected out by experiencing durable responses to TIL. Rates of recurrent irAEs from prior ICI exposure were similar to those reported with ICI rechallenge in the absence of intervening TIL therapy,13 and the incidence of grade 3+AEs was modest. These data support further development of new immuno-oncology and targeted therapy regimens for TIL-refractory advanced melanoma and the inclusion of these patients in clinical trials. Limitations include the retrospective, single-arm design and the heterogeneity of ICI regimens administered. While the majority of patients were anti-PD-1 exposed prior to TIL, a limited number of patients were anti-PD-1 naïve prior to TIL therapy, limiting relevance to current practice patterns. Additionally, this analysis does not include correlative immunologic data (eg, absolute lymphocyte count) which may be informative in predicting response to ICIs after TIL. A randomized, prospective evaluation comparing sequential combination ICI therapy and adoptive cell therapy with crossover at the time of progression in anti-PD-1 refractory melanoma (with a design akin to DREAMSeq)14 would more definitively inform optimal sequencing of these therapeutic modalities. As novel cellular therapies for solid tumors continue to show promise (eg, NCT06060613, NCT06743126), the relationship between adoptive cell transfer and ICI rechallenge may vary across cell products and tumor histologies, warranting dedicated investigation in each setting. Additionally, phenotypic characterization of infused cell products may provide insights into rational approaches for integrating ICI and cellular therapies. Supplementary material Footnotes Funding: This work was supported in part Memorial Sloan Kettering Cancer Center (MSK) NCI Core Grant P30 CA008748 (JWS, HLK, KSP, ANS). Additional support provided by the Marilyn and Michael Glosserman Foundation for Melanoma and Basal Cell Carcinoma Research (EJL). These funders had no role in the study design; in the collection, analysis and interpretation of the data; in the writing of the report; and in the decision to submit the paper for publication. Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Data availability free text: De-identified patient-level data are available upon reasonable request. Collaborators: N/A. Ethics approval: This study involves human participants and was approved by Memorial Sloan Kettering Institutional Review Board, Protocol 23-330. As a retrospective cohort study with no identifiable patient data, informed consent from individual participants was not obtained. Data availability statement Data are available upon reasonable request. References Associated Data Supplementary Materials Data Availability Statement Data are available upon reasonable request.